Virginia L. Jones

Suggest Changes
Learn More
BACKGROUND We have used doses of 60Gy or higher for neoadjuvant chemoradiotherapy for select patients with advanced non-small cell lung cancer (NSCLC), including patients with N2 disease and those(More)